Coherus Biosciences | CHRS - Le Chiffre D'Affaires De Vente





Ventes Changement Date
AbbVie USD 16.99B 1.99B 2026-06
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Akebia Therapeutics USD 57.62M 1.14M 2025-12
ALKERMES USD 496.01M 103.1M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amarin USD 49.22M 451K 2025-12
Amgen USD 10.1B 1.48B 2026-06
Baxter International USD 2.96B 260M 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 22.97B 3.17B 2026-06
Fujifilm JPY 826.49B 100.76B 2026-06
Gilead Sciences USD 7.8B 800M 2026-06
Ironwood Pharmaceuticals USD 113.04M 6.53M 2026-06
Merck USD 16.6B 310M 2026-06
Myriad Genetics USD 190.7M 9.7M 2026-06
Pacira USD 192.4M 15.4M 2026-06
Perrigo USD 1.02B 51M 2026-06
Pfizer USD 15.03B 530M 2026-06
PTC Therapeutics USD 361M 88M 2026-06
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Teva Pharmaceutical Industries USD 12.67B 900M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06
Xencor USD 51.22M 46.71M 2026-06
Zoetis USD 2.5B 200M 2026-06